denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: an educational grant from Bristol-Myers Squibb. Provided by Clinical Care Options, LLC.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Leukemia, ALL, multiple myeloma, AML, Biological, therapy sequence, apoptosis, apheresis, Adult, Diseases, CLL, Lymphoma (any), Therapies, CAR-Ts, Combinations, Elderly, Non-Hodgkin Lymphoma, Pediatric, Biological Processes, DNA damage, Technology and Procedures, Young Adult, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Myeloid Malignancies, molecular interactions
Hematology Disease Topics & Pathways:
Leukemia, ALL, multiple myeloma, AML, Biological, therapy sequence, apoptosis, apheresis, Adult, Diseases, CLL, Lymphoma (any), Therapies, CAR-Ts, Combinations, Elderly, Non-Hodgkin Lymphoma, Pediatric, Biological Processes, DNA damage, Technology and Procedures, Young Adult, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Myeloid Malignancies, molecular interactions
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Renier J. Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center
Disclosures:
Brentjens: Gracell Therapeutics: Consultancy; BMS: Research Funding; Juno Therapeutics (a Bristol Myers Squibb company): Patents & Royalties.
Speakers:
Noopur S. Raje, MD, Massachusetts General Hospital
and
Frederick L. Locke, MD, Moffitt Cancer Center
Disclosures:
Raje: Janssen: Consultancy; Immuneel: Consultancy; Celgene: Consultancy; Takeda: Consultancy; Karyopharm: Consultancy; Bristol Myers Squibb: Consultancy; Immuneel: Membership on an entity's Board of Directors or advisory committees; Caribou: Consultancy, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy, Research Funding; Amgen: Consultancy. Locke: Celgene/Bristol-Myers Squibb: Consultancy; GammaDelta Therapeutics: Consultancy; Wugen: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Calibr: Consultancy; Allogene: Consultancy; Cellular Biomedicine Group: Other: Consultancy with grant options; Novartis: Consultancy.
CAR T-cell therapy is at the leading edge of advances in the treatment of relapsed or chemotherapy-refractory leukemia, lymphoma, and myeloma. In this webinar, experts in these malignancies will use a case-based approach to examine current and future applications for CAR T-cell therapy, discussing key clinical data and providing their expert insights to maximize efficacy while appropriately managing toxicity. Throughout the webinar, attendees will interact with the experts using user-friendly technology. After each presentation, faculty will pause for a panel discussion and to answer questions from the audience. Discussion topics include:
- CAR T-Cell Therapy in Lymphomas
- CAR T-Cell Therapy for Myeloma
- CAR T-Cell Therapies for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Best Practices in Identifying and Managing CAR T-Cell–Mediated Toxicities
See more of: Satellite Symposia